La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Burcon NutraScience Bilan de santé

Santé financière contrôle des critères 1/6

Burcon NutraScience possède un total de capitaux propres de CA$3.5M et une dette totale de CA$6.5M, ce qui porte son ratio d'endettement à 187.7%. Son actif total et son passif total sont CA$10.6M et de CA$7.1M.

Informations clés

187.7%

Ratio d'endettement

CA$6.55m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CA$2.16m
Fonds propres	CA$3.49m
Total du passif	CA$7.09m
Total des actifs	CA$10.58m

Mises à jour récentes de la santé financière

Recent updates

Burcon NutraScience falls 23% postmarket on delisting of stock from Nasdaq Capital Market

Sep 02

Burcon NutraScience GAAP EPS of -C$0.04, revenue of C$90.54K

Aug 15

Burcon: Partner Bunge's $500 Million To $1 Billion Of Growth Capex Within Alternative Proteins Bodes Well

May 12

Burcon NutraScience: Achieved Several Key Milestones In 1H 2021, Significant Opportunity Ahead

Sep 03

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de BRCN.F ( CA$3.1M ) dépassent ses passifs à court terme ( CA$545.0K ).

Passif à long terme: Les actifs à court terme de BRCN.F ( CA$3.1M ) ne couvrent pas ses passifs à long terme ( CA$6.5M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de BRCN.F ( 125.7% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de BRCN.F est passé de 0% à 187.7% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: BRCN.F dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: BRCN.F dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 8.7 % chaque année

Burcon NutraScience Bilan de santé

Santé financière contrôle des critères 1/6

Informations clés

Mises à jour récentes de la santé financière

Burcon Receives Nasdaq Letter Regarding Minimum Bid Price Deficiency

Recent updates

Burcon NutraScience Corporation Announces Board Changes

Burcon NutraScience Corporation, Annual General Meeting, Sep 18, 2024

Burcon NutraScience Corporation to Report Fiscal Year 2024 Results on Jun 26, 2024

Burcon NutraScience Corporation announced that it has received CAD 4.36416 million in funding

Burcon NutraScience Corporation to Report Q3, 2024 Results on Feb 14, 2024

Burcon NutraScience Corporation to Report Q2, 2024 Results on Nov 14, 2023

Burcon NutraScience Corporation Announces Board Changes

Burcon NutraScience Corporation, Annual General Meeting, Sep 20, 2023

Burcon NutraScience Corporation to Report Fiscal Year 2023 Results on Jun 22, 2023

Burcon NutraScience Corporation announced that it has received CAD 3.41342 million in funding

Burcon NutraScience Corporation announced that it has received CAD 3.41342 million in funding

Burcon Announces Sunflower Protein Process Commercially Ready

Burcon NutraScience Corporation announced that it expects to receive CAD 3.376451 million in funding

Burcon NutraScience Corporation announced that it expects to receive CAD 3.37645 million in funding

Burcon NutraScience Corporation to Report Q3, 2023 Results on Feb 14, 2023

Burcon NutraScience Corporation Announces Board Changes

Burcon NutraScience Corporation Announces CEO Changes

Burcon NutraScience Corporation to Report Q2, 2023 Results on Nov 07, 2022

Burcon Announces Breakthrough in Sunflower Protein Development

Burcon NutraScience falls 23% postmarket on delisting of stock from Nasdaq Capital Market

First quarter 2023 earnings released: CA$0.04 loss per share (vs CA$0.029 loss in 1Q 2022)

Burcon NutraScience GAAP EPS of -C$0.04, revenue of C$90.54K

Burcon NutraScience Corporation to Report Q1, 2023 Results on Aug 15, 2022

Burcon NutraScience Corporation, Annual General Meeting, Sep 14, 2022

Full year 2022 earnings released

Burcon NutraScience Corporation to Report Fiscal Year 2022 Results on Jun 27, 2022

Burcon: Partner Bunge's $500 Million To $1 Billion Of Growth Capex Within Alternative Proteins Bodes Well

Now 21% undervalued after recent price drop

Burcon Receives Nasdaq Letter Regarding Minimum Bid Price Deficiency

Burcon NutraScience Corporation Announces Appointment of Peter H. Kappel as Interim CEO

Burcon Nutrascience Corporation Announces Resignation of Johann Tergesen as CEO, Effective February 28, 2022

Burcon NutraScience Corporation to Report Q3, 2022 Results on Feb 14, 2022

Second quarter 2022 earnings released: CA$0.01 loss per share (vs CA$0.044 profit in 2Q 2021)

Director Chi Ng has left the company

Independent Director David Ju has left the company

Director recently sold US$69k worth of stock

Burcon NutraScience: Achieved Several Key Milestones In 1H 2021, Significant Opportunity Ahead

First quarter 2022 earnings released: CA$0.029 loss per share (vs CA$0.014 loss in 1Q 2021)

Forecast breakeven pushed back to 2023

Full year 2021 earnings released

Burcon NutraScience Corporation to Report Q3, 2021 Results on Feb 16, 2021

Burcon Nutrascience Corporation Elects Rosanna Chau to the Board of Directors

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines